Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.…
Evommune to Present at Upcoming Investor Conferences
Evommune (NYSE: EVMN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 48 employees.
The shares were at 7.040 USD on 20 November 2026, down 63.5% over 52 weeks. Its 52-week range is 4.940 USD to 33.20 USD: the price is 78.8% below the high and 42.5% above the low.
Its market capitalisation is 291.10M USD.
Evommune reports return on equity of -33.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 160.45M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 21.89 USD is 210.9% above the current price. The next earnings report is expected on 4 March 2027.